: Novo Nordisk cracks down on alleged Ozempic imitations

Drug maker Novo Nordisk NVO on Tuesday sued five wellness spas and clinics in federal court, accusing them of unlawfully peddling what they said were modified copies of the popular drug Ozempic and other medications being used for weight loss, according to the Wall Street Journal. The drug maker accused those businesses of “false advertising, trademark infringement and unfair competition,” according to the Journal. It also asked the courts to require the businesses to say they had no connection with Novo Nordisk, and bar the businesses from saying their custom-made versions of Ozempic contained semaglutide, the primary ingredient of Ozempic and two other drugs made by Novo Nordisk, Wegovy and Rybelsus. Shares rose 0.5% on Tuesday.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.